---
figid: PMC3977457__pgpm-7-095Fig1
figlink: /pmc/articles/PMC3977457/figure/f1-pgpm-7-095/
number: Figure 1
caption: 'Schema outlining the activation of the human epidermal growth-factor receptor
  2 pathway and antibody blockade by trastuzumab and pertuzumab.Abbreviations: HER,
  human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor;
  IGFR, insulin-like growth-factor receptor; IV, intravenous; PI3K, phosphoinositide
  3-kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated
  kinase; mTOR, mammalian target of rapamycin.'
pmcid: PMC3977457
papertitle: 'Precision medicine and personalized breast cancer: combination pertuzumab
  therapy.'
reftext: Kerry Reynolds, et al. Pharmgenomics Pers Med. 2014;7:95-105.
pmc_ranked_result_index: '124182'
pathway_score: 0.9575259
filename: pgpm-7-095Fig1.jpg
figtitle: 'Precision medicine and personalized breast cancer: combination pertuzumab
  therapy.'
year: '2014'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3977457__pgpm-7-095Fig1.html
  '@type': Dataset
  description: 'Schema outlining the activation of the human epidermal growth-factor
    receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.Abbreviations:
    HER, human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor;
    IGFR, insulin-like growth-factor receptor; IV, intravenous; PI3K, phosphoinositide
    3-kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated
    kinase; mTOR, mammalian target of rapamycin.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - AKT2
  - FGFR1
  - FGFR3
  - ERBB3
  - IGF1R
  - MAPK1
  - MAPK3
  - AKT3
  - MTOR
  - KRAS
  - FGFR4
  - NRAS
  - FGFRL1
  - AKT1
  - ERBB2
  - FGFR2
  - MAP2K1
  - HRAS
  - Cancer
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: IGFR
  symbol: IGFR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
